# Centene Corporation – Consensus ‘buy’ rating and 14.8% Upside Potential

- Link: https://www.directorstalkinterviews.com/centene-corporation-consensus-buy-rating-and-14.8-upside-potential/4121133588
- Published: 2023-11-22T13:01:16+00:00
- Author: Charlotte Edwards

**Centene Corporation** which can be found using ticker (CNC) have now 15 confirmed
analysts covering the stock with the consensus suggesting a rating of ‘buy’. The
target price High/Low ranges between $110.00 and $72.00 calculating the mean target
price we have $83.53. Now with the previous closing price of $72.76 and the analysts
are correct then we can expect a percentage increase in value of 14.8%. The 50 day
moving average now sits at $70.25 and the 200 moving average now moves to $67.60.
The market capitalization for the company is 39.37B. The stock price is currently
at: $73.70 USD

 The potential market cap would be $45,198,285,897 based on the market consensus.

The company has a dividend yield of 1.57%. Other points of data to note are a P/
E ratio of 16.34, revenue per share of $253.50 and a 3.85% return on assets.

Centene Corporation is a healthcare company. The Company provides services to government-
sponsored and commercial healthcare programs, focusing on under-insured and uninsured
individuals. It provides a range of managed healthcare products and services, primarily
through Medicaid, Medicare, and commercial products. Its segments include Medicaid,
Medicare, Commercial and Other. It offers Medicaid and Medicare members (including
Medicare Prescription Drug Plans) as well as individuals and families served by 
the Health Insurance Marketplace and the TRICARE program. It also contracts with
other healthcare and commercial organizations to provide a variety of specialty 
services focused on treating the whole person. Medicaid program provides health 
insurance to low-income families and individuals with disabilities. Medicare is 
a federal health insurance program for people ages 65 and over, which also covers
people under 65 with certain disabilities and people with end-stage renal diseases.

Share on: